An interventional study of Aflibercept (2.0 mg) and Bevacizumab in Diabetic Macular Edema (DME), sponsored by CMH Multan Institute of Medical Sciences. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by CMH Multan Institute of Medical Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 15th largest by planned enrollment, is the only one that started in 2025, is one of 3 with no phase, and was the 52nd registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country.
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 116 is above the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
CMH Multan Institute of Medical Sciences is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
CMH Multan Institute of Medical Sciences has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetic macular edema is a frequent complication of long-standing diabetes mellitus in which fluid leaks into the central part of the retina (macula), leading to reduced vision. This randomized controlled trial will be conducted at Combined Military Hospital, Multan, to compare two commonly used intravitreal anti vascular endothelial growth factor medicines, aflibercept and bevacizumab, in adults aged 30 to 60 years with type 1 or type 2 diabetes mellitus for at least 5 years, central macular thickness of at least 300 micrometers on optical coherence tomography, and reduced baseline visual acuity (20/50 or worse). Eligible participants will be allocated in a 1:1 ratio to receive either intravitreal aflibercept 2.0 mg or intravitreal bevacizumab 1.25 mg, administered monthly for two months, with follow-up assessments at 1 and 2 months. The primary hypothesis is that aflibercept produces a greater average improvement in visual acuity than bevacizumab in this patient group. The primary outcome is the mean change in visual acuity measured as Early Treatment Diabetic Retinopathy Study letter score from baseline to 2 months. The secondary outcome is the mean change in central retinal thickness on optical coherence tomography.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intravitreal aflibercept administered as 2.0 mg injection, given monthly for two months.
Drug: Aflibercept (2.0 mg)
Participants will receive intravitreal bevacizumab administered as 1.25 mg injection, given monthly for two months
Drug: Bevacizumab
Intravitreal aflibercept 2.0 mg, administered once monthly for two consecutive months.
Intravitreal bevacizumab 1.25 mg, administered once monthly for two consecutive months.
Mean Change in Visual Acuity Letter Score
The primary outcome is the average change in visual acuity expressed as Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, calculated by converting Snellen visual acuity measurements. The change is determined by subtracting baseline letter score from the letter score measured at follow up. This metric reflects functional improvement in vision.
Time frame: Baseline assessment before first injection and follow up evaluation at the end of 2 months after initiation of treatment.
Mean Change in Central Retinal Thickness
The secondary outcome is the average change in central retinal thickness measured in micrometers using optical coherence tomography. The change is calculated by comparing baseline thickness with the value measured at follow up. This outcome reflects anatomical response of the macula to treatment.
Time frame: Baseline assessment before first injection and follow up evaluation at the end of 2 months after initiation of treatment.
Started Sep 2025 (actual). Primary completion is estimated for Feb 2026, 5 months after the start.
Of 47 non-industry interventional studies with no phase under Macular Edema, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 5 months is below that.
Counting every sponsor, half of 51 studies reached it within 18 months; a quarter within 8 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept
CMH Multan Institute of Medical Sciences